Pipeline
We are building a diverse pipeline of novel immunometabolic modulators.
​
At the core of our discovery engine lies a “specialized” library of small molecules uniquely designed to engage with lipid-binding proteins. Our profound understanding of lipid biology and the mechanisms by which our specialized drugs interacts with their target proteins to modulate immune cell metabolism guide our development efforts.
​
Discovery: Identify lead compounds that selectively engage with the biological target and influence its function in cells
In vivo proof-of concept (POC): Establish disease modifying activity of the drug candidates in relevant animal models
Lead optimization: Optimize efficacy, pharmacokinetic and toxicokinetic parameters
Investigational new drug (IND)-enabling: Perform studies required by the regulator authorities for initiating human clinical trials
*In combination with immunotherapy
1
2
3
4